ClinicalTrials.gg

Program

Clascoterone

Also written as “Winlevi (clascoterone) 1% cream”, “CB-03-01 cream, 1%” and “Clascoterone 5% solution”.

Its studies are mostly in Acne Vulgaris · Alopecia, led by 4 companies.

Furthest: phase 4, since Nov 17, 201519 company-led studies, 3 open or runningNext primary completion: Aug 7, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cassiopea SpA70 open or runningphase 3since Nov 17, 2015Nov 17, 2015none ahead
Sun Pharmaceutical Industries61 open or runningphase 4since Mar 11, 2024Mar 11, 2024none ahead
3SBio32 open or runningphase 3since Apr 30, 2024Apr 30, 2024Aug 7, 2028phase 3 · NCT07457294
Intrepid Therapeutics30 open or runningphase 2since Jun 27, 2012Jun 27, 2012none ahead

Also a collaborator on its studies: canfield-scientific-inc and icon-clinical-research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 27, 2012First study: phase 2 study in Acne VulgarisNew to Intrepid TherapeuticsIntrepid Therapeutics · NCT01631474 · 363 enrolled · United States
  2. Apr 11, 2013Phase 2 study in Acne VulgarisIntrepid Therapeutics · NCT01831960 · 42 enrolled · United States
  3. Oct 7, 2014Phase 2 study in AlopeciaIntrepid Therapeutics · NCT02279823 · 95 enrolled · United States
  4. Nov 17, 2015Cassiopea SpA's first studies: 2 phase 3 studies in Acne VulgarisNew to Cassiopea SpACassiopea SpA · NCT02608476, NCT02608450
  5. Feb 10, 2016Phase 3 study in Acne VulgarisCassiopea SpA · NCT02682264 · 609 enrolled · United States, Bulgaria, Georgia and more
  6. Mar 22, 2016Phase 2 study in Acne VulgarisCassiopea SpA · NCT02720627 · 27 enrolled · United States, Poland
  7. Jun 18, 2018Phase 1 study in Healthy VolunteersCassiopea SpA · NCT03665194 · 32 enrolled · United Kingdom
  8. Jun 6, 20232 phase 3 studies in AlopeciaCassiopea SpA · NCT05914805, NCT05910450
  9. Mar 11, 2024Sun Pharmaceutical Industries's first studies: 2 phase 4 studies in Acne VulgarisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT06336629, NCT06336603
  10. Apr 30, 20243SBio's first study: phase 3 study in Acne VulgarisNew to 3SBio3SBio · NCT06403501 · 692 planned · China
  11. May 10, 20244 phase 4 studies in Acne VulgarisSun Pharmaceutical Industries · NCT06425900, NCT06415305, NCT06415292 and 1 more
  12. May 31, 2024Phase 1 study in Acne Vulgaris3SBio · NCT06454708 · 12 enrolled · China
  13. Feb 26, 2026Phase 3 study in Acne Vulgaris3SBio · NCT07457294 · 692 planned

Ahead

  1. Aug 7, 2028Primary completion: phase 3 study in Acne Vulgaris3SBio · NCT07457294

TargetBeta

AR →read by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07457294Acne Vulgaris3Not yet recruiting3SBioAug 7, 2028692
NCT06454708Acne Vulgaris · China1Completed3SBioAug 12, 202412
NCT06425900Acne Vulgaris · United States4Active, not recruitingSun Pharmaceutical IndustriesMar 202610
NCT06415305Acne Vulgaris · United States4CompletedSun Pharmaceutical IndustriesApr 17, 202410
NCT06415292Acne Vulgaris · United States4CompletedSun Pharmaceutical IndustriesDec 16, 202350
NCT06415279Acne Vulgaris · United States4CompletedSun Pharmaceutical IndustriesFeb 12, 202540
NCT06403501Acne Vulgaris · China3Recruiting3SBioOct 2026692
NCT06336629Acne Vulgaris · United States4CompletedSun Pharmaceutical IndustriesJul 10, 202410
NCT06336603Acne Vulgaris · United States4CompletedSun Pharmaceutical IndustriesOct 29, 202420
NCT05914805Alopecia · United States, Germany, Poland3CompletedCassiopea SpAJul 16, 2025762
NCT05910450Alopecia · United States, Georgia3CompletedCassiopea SpAJan 26, 2026703
NCT03665194Healthy Volunteers · United Kingdom1CompletedCassiopea SpASep 12, 201832
NCT02720627Acne Vulgaris · United States, Poland2CompletedCassiopea SpAMar 21, 201827
NCT02682264Acne Vulgaris · United States, Bulgaria, Georgia and more3CompletedCassiopea SpAAug 31, 2018609
NCT02608476Acne Vulgaris · United States, Bulgaria, Georgia and more3CompletedCassiopea SpAFeb 21, 2018732
NCT02608450Acne Vulgaris · United States, Georgia, Ukraine3CompletedCassiopea SpAApr 11, 2018708
NCT02279823Alopecia · United States2CompletedIntrepid TherapeuticsDec 201595
NCT01831960Acne Vulgaris · United States2CompletedIntrepid TherapeuticsNov 201342
NCT01631474Acne Vulgaris · United States2CompletedIntrepid TherapeuticsFeb 2014363

How it is read

Names in the registry

  • “Winlevi (clascoterone) 1% cream”, 3 entries
  • “CB-03-01 cream, 1%”, 3 entries
  • “Clascoterone 5% solution”, 2 entries
  • “cortexolone 17α-propionate”, 2 entries
  • “CB-03-01”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.